Acadia Pharmaceuticals Inc
ACAD
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.49B
Close$
$-11.72
146% downside
Current Fair Value
146% downsideOvervalued by 146% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.49 Billion |
|---|---|
| Enterprise Value | $3.68 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.32 |
| Beta | 0.8 |
| Outstanding Shares | 170,517,000 |
Return
| Return on Equity | 30.10% |
|---|---|
| Return on Assets | 23.40% |
| Return on Invested Capital | 7.51% |
Valuation & Multiples
| P/E Ratio | 11.76 |
|---|---|
| PEG | -14.54 |
| Price to Sales | 4.25 |
| Price to Book Ratio | 3.64 |
| Enterprise Value to Revenue | 3.36 |
| Enterprise Value to EBIT | 37.65 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$0.11
Average shareholder expectationRevenue Estimate
$277.46 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$295.88 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 68.09% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.14%▼ 97.14% |
|---|---|
| Total Invested | $6.19M▼ 99.83% |
| Investors Holding | 15▼ 340.00% |
ESG Score
No data
About Acadia Pharmaceuticals Inc
CEO: Uli Hacksell